How to Buy Brooks Laboratories Ltd Shares?
You can easily buy the stocks/shares of Brooks Laboratories Ltd (BROOKS) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Brooks Laboratories Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of BROOKS as on 15th May 2025 is ₹133.55What is the return on Brooks Laboratories Ltd share?
The past returns of Brooks Laboratories Ltd (BROOKS) share are- Past 1 week: N/A
- Past 1 month: -96.42
- Past 3 months: 23.48
- Past 6 months: -16.69
- Past 1 year: 52.45
- Past 3 years: 31.60
- Past 5 years: 318.93
What is the Dividend yield % on Brooks Laboratories Ltd share?
The current dividend yield of Brooks Laboratories Ltd (BROOKS) is N/AWhat is the Market Cap of Brooks Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Brooks Laboratories Ltd (BROOKS) is ₹369.73Cr as of 15th May 2025What is the 52 Week High and Low of Brooks Laboratories Ltd?
The 52-week high and low of Brooks Laboratories Ltd (BROOKS) is ₹198.86 and ₹80.64.What is the PE and PB ratio of Brooks Laboratories Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Brooks Laboratories Ltd are -37.08 and 5.64 respectively.Which sector does Brooks Laboratories Ltd belong to?
Brooks Laboratories Ltd (BROOKS) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.What are the peers or stocks similar to Brooks Laboratories Ltd?
The peers or stocks similar to Brooks Laboratories Ltd are: and many others.Can't decide whether or not to buy Brooks Laboratories Ltd?
Worry no more! Login to Tickertape and check out Brooks Laboratories Ltd (BROOKS) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Brooks Laboratories Ltd?
The 52-week high and low of Brooks Laboratories Ltd (BROOKS) is ₹198.86 and ₹80.64.1. Test Stocks FAQ for Brooks Laboratories Ltd Shares?
You can easily buy the stocks/shares of Brooks Laboratories Ltd (BROOKS) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Brooks Laboratories Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of BROOKS as on 15th May 2025 is ₹133.55
Brooks Laboratories Ltd
BROOKS Share Price
133.551.04% (-1.41)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
BROOKS Performance & Key Metrics
BROOKS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -37.12 | 5.64 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
BROOKS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BROOKS Company Profile
Brooks Laboratories Ltd. is a Contract Manufacturing Company. The Company manufacturers molecules in Injectables and Clavulanic Acid range in Tablets and Dry Syrups.
DIVISLAB
PE Ratio
80.67
80.67
1Y Return
45.14%
45.14%
Buy Reco %
28.57
28.57
SYNGENE
PE Ratio
52.81
52.81
1Y Return
6.24%
6.24%
Buy Reco %
87.50
87.50
AARTIPHARM
PE Ratio
29.43
29.43
1Y Return
48.50%
48.50%
Buy Reco %
—
—
PE Ratio
1,350.95
1,350.95
1Y Return
60.91%
60.91%
Buy Reco %
50.00
50.00
VIMTALABS
PE Ratio
33.92
33.92
1Y Return
105.40%
105.40%
Buy Reco %
—
—
BROOKS Sentiment Analysis
BROOKS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
BROOKS Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
BROOKS Stock Growth Drivers
BROOKS Stock Growth Drivers
3Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
BROOKS Stock Challenges
BROOKS Stock Challenges
1Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
BROOKS Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
BROOKS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BROOKS
BROOKS
Income
Balance Sheet
Cash Flow
Annual Normal View
BROOKS Income Statement
BROOKS Income Statement
Annual Normal View
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 77.99 | 91.98 | 63.77 | 80.45 | 83.44 | 83.47 | ||||||
Raw Materials | 51.77 | 66.28 | 47.45 | 56.59 | 90.60 | 90.63 | ||||||
| Power & Fuel Cost | 2.70 | 3.99 | 3.23 | 1.73 | ||||||||
| Employee Cost | 12.04 | 16.85 | 16.00 | 10.09 | ||||||||
| Selling & Administrative Expenses | 6.21 | 8.57 | 6.21 | 4.05 | ||||||||
| Operating & Other expenses | 4.01 | 9.75 | 20.04 | 24.93 | ||||||||
EBITDA | 1.26 | -13.46 | -29.16 | -16.94 | -7.16 | -7.16 | ||||||
| Depreciation/Amortization | 7.14 | 7.35 | 7.03 | 1.77 | 1.60 | 1.60 | ||||||
| PBIT | -5.88 | -20.81 | -36.19 | -18.71 | -8.76 | -8.76 | ||||||
| Interest & Other Items | 3.10 | 3.10 | 2.18 | 0.84 | 1.03 | 1.02 | ||||||
| PBT | -8.98 | -23.91 | -38.37 | -19.55 | -9.79 | -9.78 | ||||||
| Taxes & Other Items | 10.38 | -12.61 | -17.47 | 0.03 | 0.18 | 0.18 | ||||||
| Net Income | -19.36 | -11.30 | -20.90 | -19.58 | -9.97 | -9.96 | ||||||
| EPS | -7.76 | -4.53 | -8.38 | -7.65 | -373.00 | -3.79 | ||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
BROOKS Company Updates
BROOKS Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
BROOKS Past Performance & Peer Comparison
BROOKS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation-basic on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Brooks Laboratories Ltd | -37.08 | 5.64 | — |
| Divi's Laboratories Ltd | 80.67 | 13.02 | 0.45% |
| Syngene International Ltd | 52.81 | 6.15 | 0.19% |
| Aarti Pharmalabs Ltd | 29.43 | 4.56 | 0.57% |
BROOKS Stock Price Comparison
Compare BROOKS with any stock or ETFCompare BROOKS with any stock or ETF
BROOKS
BROOKS Holdings
BROOKS Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
BROOKS Promoter Holdings Trend
BROOKS Promoter Holdings Trend
BROOKS Institutional Holdings Trend
BROOKS Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 2.17%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BROOKS Shareholding Pattern
BROOKS Shareholding Pattern
BROOKS Shareholding History
BROOKS Shareholding History
Foreign Institutions
Mutual Funds Invested in BROOKS
Mutual Funds Invested in BROOKS
No mutual funds holding trends are available
Top 1 Mutual Funds holding Brooks Laboratories Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 11.3046% | Percentage of the fund’s portfolio invested in the stock 3.14% | Change in the portfolio weight of the stock over the last 3 months 0.69% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/46 (0) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing BROOKS stock
smallcases containing BROOKS stock
Looks like this stock is not in any smallcase yet.
BROOKS Events
BROOKS Events
BROOKS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BROOKS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
BROOKS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BROOKS has not given any dividends in last 5 years
BROOKS Dividends
BROOKS Dividends
Hmm, looks like data is unavailable here. Please come back after some timeBROOKS Stock News & Opinions
BROOKS Stock News & Opinions
Articles & Videos
Earnings
Brooks Laboratories reports consolidated net loss of Rs 1.46 crore in the March 2025 quarter
Net Loss of Brooks Laboratories reported to Rs 1.46 crore in the quarter ended March 2025 as against net loss of Rs 9.61 crore during the previous quarter ended March 2024. Sales rose 31.60% to Rs 23.32 crore in the quarter ended March 2025 as against Rs 17.72 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 9.97 crore in the year ended March 2025 as against net loss of Rs 19.59 crore during the previous year ended March 2024. Sales rose 3.86% to Rs 82.56 crore in the year ended March 2025 as against Rs 79.49 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales23.3217.72 32 82.5679.49 4 OPM %-5.36-53.78 --9.74-22.48 - PBDT-0.90-9.15 90 -8.19-17.79 54 PBT-1.28-9.61 87 -9.79-19.57 50 NP-1.46-9.61 85 -9.97-19.59 49 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Brooks Laboratories standalone net profit rises 356.67% in the March 2025 quarter
Net profit of Brooks Laboratories rose 356.67% to Rs 1.37 crore in the quarter ended March 2025 as against Rs 0.30 crore during the previous quarter ended March 2024. Sales rose 31.60% to Rs 23.32 crore in the quarter ended March 2025 as against Rs 17.72 crore during the previous quarter ended March 2024. For the full year,net profit rose 99.35% to Rs 3.05 crore in the year ended March 2025 as against Rs 1.53 crore during the previous year ended March 2024. Sales rose 3.86% to Rs 82.56 crore in the year ended March 2025 as against Rs 79.49 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales23.3217.72 32 82.5679.49 4 OPM %6.782.14 -6.034.09 - PBDT1.940.76 155 4.833.33 45 PBT1.550.30 417 3.231.56 107 NP1.370.30 357 3.051.53 99 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Brooks Laboratories to table results
Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Brooks Laboratories reports consolidated net loss of Rs 4.57 crore in the December 2024 quarter
Net Loss of Brooks Laboratories reported to Rs 4.57 crore in the quarter ended December 2024 as against net loss of Rs 3.88 crore during the previous quarter ended December 2023. Sales rose 76.78% to Rs 38.45 crore in the quarter ended December 2024 as against Rs 21.75 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales38.4521.75 77 OPM %-8.89-15.49 - PBDT-3.76-3.42 -10 PBT-4.55-3.85 -18 NP-4.57-3.88 -18 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Brooks Laboratories to declare Quarterly Results
Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Brooks Laboratories to conduct board meeting
Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 11 December 2024Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Brooks Laboratories reports consolidated net loss of Rs 3.96 crore in the September 2024 quarter
Net Loss of Brooks Laboratories reported to Rs 3.96 crore in the quarter ended September 2024 as against net loss of Rs 1.64 crore during the previous quarter ended September 2023. Sales declined 14.51% to Rs 20.79 crore in the quarter ended September 2024 as against Rs 24.32 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales20.7924.32 -15 OPM %-16.40-4.52 - PBDT-3.53-1.20 -194 PBT-3.96-1.64 -141 NP-3.96-1.64 -141 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Brooks Laboratories schedules board meeting
Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Brooks Laboratories to conduct AGM
Brooks Laboratories announced that the 22th Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Brooks Laboratories to hold AGM
Brooks Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
In last 6 months, promoter holding in the company has decreased by 10.97%
Pledged promoter holdings is insignificant